PEDIATRIC ONCOLOGY GROUP

要求支持参与所有临床和实验室 儿科肿瘤组（POG）的研究活动。 具体来说，这些资金将协助我们在合作癌症方面的努力， 使用手术和/或放射组合的治疗试验 用于治疗白血病，淋巴瘤， 实体瘤和脑瘤。 重点将放在综合 III期随机前瞻性多模态治疗方案 问题研究 我们还将参与集团范围内的第二阶段研究， 化疗剂。 我们计划充分参与有限的儿科 新药物的I期研究。 (This是合同提案的主题 从几个POG机构，包括我们自己，到NCI）。 我们将 参与研究各种儿科疾病的生物学， 恶性肿瘤，包括免疫学和药理学特征;研究中 治疗对存活患者的后期影响;以及 流行病学研究。 支持将允许我们输入研究中的最大患者数量， 确保完整记录患者数据，包括运输 样本送至参考实验室。 它将允许成员参加POG 会议，并参加工作小组委员会，礼宾规划 委员会和研究写作委员会。 此外，它将允许 某些调查人员继续发挥领导作用， 科学和管理的POG。 博士V. Michael Whitehead是New Agents & Pharmacology的联合主席 科学支持委员会。 在这个职位上，他指导第一阶段， II期新药研究。 他正在制定研究方案， 甲氨蝶呤、6-巯基嘌呤和阿糖胞苷的药理学 儿童急性淋巴细胞白血病 他是规划委员会的成员。 ALinC 14委员会，下一个急性白血病一线治疗研究 淋巴母细胞白血病 Carol Freeman博士是第一阶段的协调员 儿童脑干胶质瘤超分割治疗研究（POG 8495） 以下POG委员会的成员：机构绩效审查 委员会和脑肿瘤核心委员会。 彭妮·科赫博士是 骨髓移植核心委员会主席 苏珊·卡贾克斯是 数据经理核心委员会

Support is requested for participation in all clinical and laboratory investigative activities of the Pediatric Oncology Group (POG). Specifically, these funds will assist our efforts in cooperative cancer therapy trials which utilize a combination of surgery and/or radiation therapy and/or chemotherapy for the treatment of leukemias, lymphomas, solid tumors and brain tumors. Emphasis will be placed on integrated multi-modality treatment programs in Phase III randomized prospective studies. We shall also participate in group-wide Phase II studies of new chemotherapeutic agents. We plan to participate fully in limited Pediatric Phase I studies of new agents. (This is the subject of a contract proposal from several POG institutions, including ourselves, to the NCI). We shall participate in studies examining the biology of various pediatric malignancies including immunologic and pharmacologic features; in studies of the late effects of therapy in surviving patients; and in epidemiological studies. Support will permit us to enter the maximum number of patients on study and ensure complete documentation of patient data, including transport of specimens to reference laboratories. It will permit members to attend POG meetings and to participate in working sub-committees, protocol planning committees and study writing committees. In addition it will permit certain investigators to continue to contribute in leadership roles to the science and administration of the POG. Dr. V. Michael Whitehead is Co-Chairman of the New Agents & Pharmacology Scientific Support Committee. In this position, he directs Phase I and Phase II new agent studies. He is developing protocols to study the pharmacology of methotrexate, 6-mercaptopurine and cytosine arabinoside in children with acute lymphoblastic leukemia. He is a member of the Planning Committee for ALinC 14, the next frontline therapeutic study of acute lymphoblastic leukemia. Dr. Carol Freeman is Coordinator of the Phase I study of Hyperfractionation in Brainstem Gliomas in Children (POG 8495) and a member of the following POG committees: Institutional Performance Review Committee and the Brain Tumor Core Committee. Dr. Penny Koch is a member of the Bone Marrow Transplant Core Committee. Susan Kajaks is a member of the Data Managers Core Committee.